Latham & Watkins advised Amneal Pharmaceuticals Holding GmbH, a subsidiary of Amneal Pharmaceuticals LLC – the seventh largest generic pharmaceutical company in the U.S. – in the acquisition of all shares in bioeq pharma GmbH, which provides generic medicinal products for the German pharmaceutical market, from Farmaprojects S.A.U.
Amneal Pharmaceuticals LLC, headquartered in Bridgewater, New Jersey, develops, manufactures and distributes generic pharmaceutical products and is currently the seventh largest U.S. generics manufacturer in number of prescriptions. It is one of the fastest growing generic pharmaceutical companies and is expanding internationally with global operations in Switzerland, UK, Ireland, India, Spain, Denmark, Germany and Australia.
The Latham & Watkins corporate team spanned the firm’s German and Spanish offices and comprised partner Harald Selzner in Düsseldorf, partner Ignacio Pallarés in Madrid and partner Christoph Engeler in Hamburg, counsel Christian Engelhardt in Hamburg, with associates Natalie Daghles in Düsseldorf and Ignacio Domínguez in Madrid.